Jazz Pharmaceuticals Plc Stock Debt To Equity

JAZZ Stock

USD 108.93 1.56 1.41%

Jazz Pharmaceuticals PLC fundamentals help investors to digest information that contributes to Jazz Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Jazz Stock. The fundamental analysis module provides a way to measure Jazz Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Jazz Pharmaceuticals stock.

		Last Reported	Projected for Next Year
	Debt To Equity	1.53	1.61

Debt To Equity is likely to rise to 1.61 in 2024.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Jazz Pharmaceuticals PLC Company Debt To Equity Analysis

Jazz Pharmaceuticals' Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.

D/E

Total Debt

Total Equity

More About Debt To Equity | All Equity Analysis

Current Jazz Pharmaceuticals Debt To Equity

2.12 %

Most of Jazz Pharmaceuticals' fundamental indicators, such as Debt To Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Jazz Pharmaceuticals PLC is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Jazz Debt To Equity Driver Correlations

Understanding the fundamental principles of building solid financial models for Jazz Pharmaceuticals is extremely important. It helps to project a fair market value of Jazz Stock properly, considering its historical fundamentals such as Debt To Equity. Since Jazz Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Jazz Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Jazz Pharmaceuticals' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Long Term Debt	Net Receivables	Good Will	Short Term Investments	Total Liab	Total Current Assets	Intangible Assets	Property Plant Equipment	Current Deferred Revenue	Short Term Debt	Common Stock	Net Tangible Assets	Capital Surpluse	Deferred Long Term Liab	Long Term Debt Total	Short Long Term Debt	Net Invested Capital	Long Term Investments	Net Working Capital	Capital Stock
Total Assets		0.91	0.97	0.75	0.96	0.98	0.98	0.99	0.3	0.98	0.93	0.98	0.95	0.6	0.61	0.5	-0.88	0.91	0.65	0.96	-0.13	0.9	0.69	0.82	-0.56
Total Stockholder Equity	0.91		0.78	0.93	0.81	0.8	0.89	0.91	0.58	0.82	0.91	0.85	0.9	0.52	0.56	0.65	-0.64	0.88	0.48	0.77	-0.26	0.7	0.76	0.82	-0.45
Net Debt	0.97	0.78		0.59	0.96	0.99	0.93	0.95	0.12	0.99	0.83	0.98	0.91	0.56	0.56	0.33	-0.96	0.85	0.65	0.98	-0.06	0.94	0.62	0.75	-0.55
Retained Earnings	0.75	0.93	0.59		0.61	0.61	0.74	0.76	0.69	0.63	0.76	0.69	0.81	0.41	0.43	0.59	-0.44	0.77	0.36	0.57	-0.39	0.48	0.73	0.71	-0.3
Accounts Payable	0.96	0.81	0.96	0.61		0.97	0.96	0.95	0.17	0.98	0.88	0.94	0.94	0.66	0.64	0.39	-0.9	0.84	0.67	0.98	0.02	0.92	0.69	0.75	-0.64
Long Term Debt	0.98	0.8	0.99	0.61	0.97		0.95	0.96	0.12	1.0	0.86	0.98	0.9	0.54	0.55	0.4	-0.95	0.87	0.66	0.98	-0.1	0.94	0.61	0.76	-0.54
Net Receivables	0.98	0.89	0.93	0.74	0.96	0.95		0.97	0.37	0.96	0.96	0.92	0.94	0.67	0.71	0.47	-0.83	0.88	0.72	0.96	-0.04	0.87	0.71	0.84	-0.64
Good Will	0.99	0.91	0.95	0.76	0.95	0.96	0.97		0.27	0.97	0.9	0.98	0.94	0.59	0.59	0.58	-0.89	0.9	0.68	0.94	-0.19	0.86	0.67	0.76	-0.55
Short Term Investments	0.3	0.58	0.12	0.69	0.17	0.12	0.37	0.27		0.16	0.53	0.15	0.33	0.35	0.49	0.22	0.13	0.36	0.11	0.16	0.02	0.11	0.62	0.62	-0.27
Total Liab	0.98	0.82	0.99	0.63	0.98	1.0	0.96	0.97	0.16		0.88	0.98	0.91	0.59	0.6	0.41	-0.94	0.87	0.69	0.99	-0.07	0.94	0.62	0.77	-0.58
Total Current Assets	0.93	0.91	0.83	0.76	0.88	0.86	0.96	0.9	0.53	0.88		0.83	0.86	0.65	0.74	0.49	-0.68	0.86	0.62	0.88	0.01	0.82	0.71	0.92	-0.62
Intangible Assets	0.98	0.85	0.98	0.69	0.94	0.98	0.92	0.98	0.15	0.98	0.83		0.93	0.51	0.49	0.47	-0.94	0.88	0.6	0.94	-0.2	0.89	0.63	0.72	-0.48
Property Plant Equipment	0.95	0.9	0.91	0.81	0.94	0.9	0.94	0.94	0.33	0.91	0.86	0.93		0.62	0.58	0.44	-0.82	0.87	0.59	0.9	-0.18	0.81	0.77	0.74	-0.56
Current Deferred Revenue	0.6	0.52	0.56	0.41	0.66	0.54	0.67	0.59	0.35	0.59	0.65	0.51	0.62		0.95	0.15	-0.49	0.42	0.74	0.68	0.47	0.49	0.45	0.45	-0.93
Short Term Debt	0.61	0.56	0.56	0.43	0.64	0.55	0.71	0.59	0.49	0.6	0.74	0.49	0.58	0.95		0.16	-0.44	0.46	0.72	0.69	0.51	0.53	0.47	0.61	-0.92
Common Stock	0.5	0.65	0.33	0.59	0.39	0.4	0.47	0.58	0.22	0.41	0.49	0.47	0.44	0.15	0.16		-0.32	0.62	0.35	0.32	-0.45	0.27	0.34	0.32	-0.05
Net Tangible Assets	-0.88	-0.64	-0.96	-0.44	-0.9	-0.95	-0.83	-0.89	0.13	-0.94	-0.68	-0.94	-0.82	-0.49	-0.44	-0.32		-0.76	-0.65	-0.93	0.1	-0.89	-0.46	-0.55	0.47
Capital Surpluse	0.91	0.88	0.85	0.77	0.84	0.87	0.88	0.9	0.36	0.87	0.86	0.88	0.87	0.42	0.46	0.62	-0.76		0.51	0.82	-0.26	0.86	0.71	0.83	-0.28
Deferred Long Term Liab	0.65	0.48	0.65	0.36	0.67	0.66	0.72	0.68	0.11	0.69	0.62	0.6	0.59	0.74	0.72	0.35	-0.65	0.51		0.73	0.16	0.52	0.35	0.38	-0.73
Long Term Debt Total	0.96	0.77	0.98	0.57	0.98	0.98	0.96	0.94	0.16	0.99	0.88	0.94	0.9	0.68	0.69	0.32	-0.93	0.82	0.73		0.05	0.93	0.61	0.76	-0.67
Short Long Term Debt	-0.13	-0.26	-0.06	-0.39	0.02	-0.1	-0.04	-0.19	0.02	-0.07	0.01	-0.2	-0.18	0.47	0.51	-0.45	0.1	-0.26	0.16	0.05		0.05	-0.11	0.04	-0.51
Net Invested Capital	0.9	0.7	0.94	0.48	0.92	0.94	0.87	0.86	0.11	0.94	0.82	0.89	0.81	0.49	0.53	0.27	-0.89	0.86	0.52	0.93	0.05		0.57	0.81	-0.44
Long Term Investments	0.69	0.76	0.62	0.73	0.69	0.61	0.71	0.67	0.62	0.62	0.71	0.63	0.77	0.45	0.47	0.34	-0.46	0.71	0.35	0.61	-0.11	0.57		0.7	-0.38
Net Working Capital	0.82	0.82	0.75	0.71	0.75	0.76	0.84	0.76	0.62	0.77	0.92	0.72	0.74	0.45	0.61	0.32	-0.55	0.83	0.38	0.76	0.04	0.81	0.7		-0.41
Capital Stock	-0.56	-0.45	-0.55	-0.3	-0.64	-0.54	-0.64	-0.55	-0.27	-0.58	-0.62	-0.48	-0.56	-0.93	-0.92	-0.05	0.47	-0.28	-0.73	-0.67	-0.51	-0.44	-0.38	-0.41

Click cells to compare fundamentals

High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.

Competition

Predict Jazz Pharmaceuticals

Debt To Equity Over Time

Jazz Total Stockholder Equity

Total Stockholder Equity

3.92 Billion

At this time, Jazz Pharmaceuticals' Total Stockholder Equity is fairly stable compared to the past year.

According to the company disclosure, Jazz Pharmaceuticals PLC has a Debt To Equity of 2.118%. This is 96.04% lower than that of the Pharmaceuticals sector and 89.06% lower than that of the Health Care industry. The debt to equity for all United States stocks is 95.65% higher than that of the company.

Jazz Debt To Equity Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Jazz Pharmaceuticals' direct or indirect competition against its Debt To Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Jazz Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Jazz Pharmaceuticals by comparing valuation metrics of similar companies.

Jazz Pharmaceuticals is currently under evaluation in debt to equity category among related companies.

Jazz Pharmaceuticals ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Jazz Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Jazz Pharmaceuticals' managers, analysts, and investors.

Environmental

Governance

Social

Jazz Fundamentals

	Return On Equity	0.0941
	Return On Asset	0.0407
	Profit Margin	0.09 %
	Operating Margin	0.12 %
	Current Valuation	10.93 B
	Shares Outstanding	63.04 M
	Shares Owned By Insiders	2.77 %
	Shares Owned By Institutions	97.38 %
	Number Of Shares Shorted	3.6 M
	Price To Earning	35.18 X
	Price To Book	1.84 X
	Price To Sales	1.80 X
	Revenue	3.83 B
	Gross Profit	3.39 B
	EBITDA	1.3 B
	Net Income	414.83 M
	Cash And Equivalents	899.36 M
	Cash Per Share	14.28 X
	Total Debt	5.8 B
	Debt To Equity	2.12 %
	Current Ratio	3.16 X
	Book Value Per Share	58.65 X
	Cash Flow From Operations	1.09 B
	Short Ratio	6.62 X
	Earnings Per Share	4.83 X
	Price To Earnings To Growth	0.84 X
	Target Price	181.24
	Number Of Employees	2.8 K
	Beta	0.63
	Market Capitalization	6.97 B
	Total Asset	11.39 B
	Retained Earnings	878.66 M
	Working Capital	1.9 B
	Current Asset	1.26 B
	Current Liabilities	226.64 M
	Net Asset	11.39 B

About Jazz Pharmaceuticals Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Jazz Pharmaceuticals PLC's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Jazz Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Jazz Pharmaceuticals PLC based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
CRM	Salesforce
MSFT	Microsoft

When determining whether Jazz Pharmaceuticals PLC offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Jazz Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Jazz Pharmaceuticals Plc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Jazz Pharmaceuticals Plc Stock:

How To Invest In Jazz

Details

Is Jazz Stock a good investment?

Details

What is Jazz Pharmaceuticals' Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Jazz Pharmaceuticals Piotroski F Score and Jazz Pharmaceuticals Altman Z Score analysis.

Note that the Jazz Pharmaceuticals PLC information on this page should be used as a complementary analysis to other Jazz Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.

Complementary Tools for Jazz Stock analysis

When running Jazz Pharmaceuticals' price analysis, check to measure Jazz Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Jazz Pharmaceuticals is operating at the current time. Most of Jazz Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Jazz Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Jazz Pharmaceuticals' price. Additionally, you may evaluate how the addition of Jazz Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

	Performance Analysis Check effects of mean-variance optimization against your current asset allocation
	Insider Screener Find insiders across different sectors to evaluate their impact on performance
	Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
	Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets
	Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum
	Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
	Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios
	Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
	ETFs Find actively traded Exchange Traded Funds (ETF) from around the world
	Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules
	Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities
	Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences

Is Jazz Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Jazz Pharmaceuticals. If investors know Jazz will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Jazz Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

1.757

Earnings Share

4.83

Revenue Per Share

60.956

Quarterly Revenue Growth

0.01

Return On Assets

0.0407

The market value of Jazz Pharmaceuticals PLC is measured differently than its book value, which is the value of Jazz that is recorded on the company's balance sheet. Investors also form their own opinion of Jazz Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Jazz Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Jazz Pharmaceuticals' market value can be influenced by many factors that don't directly affect Jazz Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Jazz Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Jazz Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Jazz Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Jazz Pharmaceuticals Plc Stock Debt To Equity

Jazz Pharmaceuticals PLC Company Debt To Equity Analysis

D/E

Total Debt

Total Equity

Current Jazz Pharmaceuticals Debt To Equity

Jazz Debt To Equity Driver Correlations

Jazz Total Stockholder Equity

Total Stockholder Equity

3.92 Billion

Jazz Debt To Equity Peer Comparison

Jazz Pharmaceuticals ESG Sustainability

Jazz Fundamentals

About Jazz Pharmaceuticals Fundamental Analysis

Also Currently Popular

Complementary Tools for Jazz Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY